Marker Therapeutics Inc (MRKR)

[poods]

Good points. From here the SP will be driven by data and any deals that can be struck, however a clear statement from the company regarding how they plan to proceed with solid tumors would be welcomed by the market, IMO. More antigens? Higher dosing? Earlier dosing? Longer dosing? Combinations with checkpoint inhibitors?
For any patient that is progressing on or off chemo in TACTOPS, they could P1 or compassionate use new antigens in pep mixes. These unfortunate patients have essentially received a death sentence so it is either hospice or a supercharged pep mix, perhaps with follow on checkpoint antibodies.
I'd like to see an aggressive, pro-patient plan outlined, that pulls out all stops for pancreatic cancer.
All that is needed is another CR in TACTOPS and it would be quite clear that Multi-TAA is active in PC, as CRs are so rare with chemo alone. The first one could have been chance, but not a second one IMO (at least the probability of 2 is remote in such a small trial).